Last reviewed · How we verify
mazindol extended release
At a glance
| Generic name | mazindol extended release |
|---|---|
| Also known as | NLS-2 |
| Sponsor | NLS Pharmaceutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 (PHASE3)
- An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy (PHASE2)
- Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |